Skip to content

Research Desk

Research
Equity Research
Backtesting Strategies
Quant Reports
SEC What Changed
Subscribe
About

Search

Research

BSX

Research TypeAsset ClassTickerRating

2026·06·14

Equity Research

BSX

Boston Scientific (BSX): Growth, Cash Flow, and Reimbursement Risk — Analysis

Boston Scientific (BSX) is rated Buy as double-digit growth and improving free cash flow support a premium valuation. Q1 2026 revenue rose 11.6% and EBITDA…

Read note →: Boston Scientific (BSX): Growth, Cash Flow, and Reimbursement Risk — Analysis

lf0

Systematic research for evidence-led investors.

Research

All Research
Equity Research
Newsletter

Site

About
Contact
Subscribe

Legal

Disclaimer
Privacy Policy

lf0 publishes research and educational commentary only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell securities. Research may rely on historical data, assumptions, and backtests that may not reflect live trading results. Past performance does not guarantee future results.

© 2026 lf0